Ubs Group Ag Forte Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 13, 2024	BUY	$0.46 - $0.78 $11,167 - $18,936	24,277 Added 73566.67%	24,310 $13,000
Q1 2024 May 13, 2024	SELL	$0.48 - $0.85 $54 - $96	-113 Reduced 77.4%	33 $0
Q4 2023 Feb 09, 2024	SELL	$0.38 - $0.82 $883 - $1,906	-2,325 Reduced 94.09%	146 $0
Q3 2023 Nov 09, 2023	BUY	$0.65 - $1.04 $1,584 - $2,535	2,438 Added 7387.88%	2,471 $1,000
Q2 2023 Aug 11, 2023	SELL	$0.98 - $1.11 $9,297 - $10,530	-9,487 Reduced 99.65%	33 $0
Q1 2023 May 12, 2023	BUY	$0.98 - $1.06 $7,648 - $8,273	7,805 Added 455.1%	9,520 $9,000
Q4 2022 Feb 08, 2023	BUY	$0.96 - $28.0 $1,614 - $47,096	1,682 Added 5096.97%	1,715 $1,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $27.75 $1,970 - $51,587	-1,859 Reduced 98.26%	33 $0
Q2 2022 Aug 10, 2022	SELL	$1.07 - $1.55 $298 - $432	-279 Reduced 12.85%	1,892 $2,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.24 $11,306 - $20,930	-9,344 Reduced 81.15%	2,171 $3,000
Q4 2021 Feb 14, 2022	BUY	$2.02 - $3.36 $22,654 - $37,682	11,215 Added 3738.33%	11,515 $25,000
Q3 2021 Nov 15, 2021	SELL	$2.96 - $36.67 $953 - $11,807	-322 Reduced 51.77%	300 $1,000
Q2 2021 Aug 13, 2021	BUY	$31.5 - $42.5 $10,143 - $13,685	322 Added 107.33%	622 $21,000
Q1 2021 May 12, 2021	SELL	$25.01 - $40.24 $10,004 - $16,096	-400 Reduced 57.14%	300 $10,000
Q4 2020 Feb 11, 2021	BUY	$28.66 - $46.79 $515 - $842	18 Added 2.64%	700 $26,000
Q3 2020 Nov 12, 2020	BUY	$14.71 - $50.69 $10,032 - $34,570	682 New	682 $34,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$3.19 Million
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $371M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.